Dashboard
Manage Tickers

ATOS


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

dominos-pizza-to-510-here-are-10-top-analyst-forecasts-for-wednesday
Domino's Pizza To $510? Here Are 10 Top An...
09/11/2024 13:08:03

ascendiant-capital-maintains-buy-on-atossa-therapeutics-raises-price-target-to-65
Ascendiant Capital Maintains Buy on Atossa...
09/11/2024 09:46:11

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

atossa-therapeutics-announces-support-of-final-rule-from-fda-requiring-patient-notification-of-breast-density-for-breast-cancer
Atossa Therapeutics Announces Support Of F...
09/10/2024 12:31:17

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced its support of the U.S. Fo...

atossa-therapeutics-granted-new-patent-directed-to-compositions-comprising-endoxifen-and-an-anteric-material-in-which-at-least-90-of-the-endoxifen-is-z-endoxifen
Atossa Therapeutics Granted New Patent Dir...
08/28/2024 12:33:34

atossa-therapeutics-and-quantum-leap-healthcare-collaborative-dose-first-patient-in-clinical-trial-evaluating-z-endoxifen-with-abemaciclib-as-neoadjuvant-treatment-for-high-risk-erher2--breast-cancer
Atossa Therapeutics And Quantum Leap Healt...
08/21/2024 12:30:51

hc-wainwright--co-reiterates-buy-on-atossa-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Atos...
08/12/2024 17:53:30

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $6 price ...

atossa-therapeutics-q2-eps-005-beats-006-estimate
Atossa Therapeutics Q2 EPS $(0.05) Beats $...
08/12/2024 12:36:53

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

atossa-therapeutics-completes-enrollment-of-80mg-pharmacokinetic-run-in-cohort-in-phase-2-evangeline-clinical-trial-evaluating-z-endoxifen-for-er--her2--breast-cancer
Atossa Therapeutics Completes Enrollment O...
07/22/2024 12:33:45

atossa-therapeutics-appoints-heather-rees-as-new-cfo
Atossa Therapeutics Appoints Heather Rees ...
07/02/2024 20:16:04

Rees most recently served as Atossa's Senior Vice President of Finance and Principal Accounting Officer. 

hc-wainwright--co-reiterates-buy-on-atossa-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Atos...
06/28/2024 15:12:47

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $6 price ...

atossa-therapeutics-announces-updated-protocol-for-clinical-trial-evaluating-z-endoxifen-in-combination-with-abemaciclib-in-women-with-erher2--breast-cancer
Atossa Therapeutics Announces Updated Prot...
06/28/2024 12:36:28

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced protocol changes in the pre...

cantor-fitzgerald-reiterates-overweight-on-atossa-therapeutics
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:26:50

Cantor Fitzgerald analyst Louise Chen reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Overweight.

atossa-to-join-russell-3000-index
Atossa To Join Russell 3000 Index
06/17/2024 12:34:29

ascendiant-capital-maintains-buy-on-atossa-therapeutics-raises-price-target-to-625
Ascendiant Capital Maintains Buy on Atossa...
06/06/2024 17:07:25

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

atossa-therapeutics-last-patient-its-phase-2-karisma-endoxifen-clinical-trial-recieved-their-final-dose
Atossa Therapeutics Last Patient Its Phase...
05/15/2024 12:39:30

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced that the last patient in th...

cantor-fitzgerald-reiterates-overweight-on-atossa-therapeutics
Cantor Fitzgerald Reiterates Overweight on...
05/14/2024 13:25:09

Cantor Fitzgerald analyst Louise Chen reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Overweight.

hc-wainwright--co-maintains-buy-on-atossa-therapeutics-raises-price-target-to-6
HC Wainwright & Co. Maintains Buy on Atoss...
05/13/2024 16:54:59

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price tar...

atossa-therapeutics-q1-2024-adj-eps-005-beats-007-estimate
Atossa Therapeutics Q1 2024 Adj EPS $(0.05...
05/13/2024 12:54:22

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

atossa-therapeutics-announces-support-of-new-breast-cancer-screening-guidelines
Atossa Therapeutics Announces Support Of N...
05/07/2024 12:46:50

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced its support of new guidelin...

atossa-therapeutics-announces-expanded-research-agreement-with-weill-cornell-medicine-to-further-evaluate-synergy-between-antibody-drug-conjugates-and-z-endoxifen
Atossa Therapeutics Announces Expanded Res...
04/29/2024 12:34:28

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreem...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION